Improving Traffic Efficiency in a Road Network by Adopting Decentralised Multi-Agent Reinforcement Learning and Smart Navigation

In the future, mixed traffic flow will consist of human-driven vehicles (HDVs) and connected autonomous vehicles (CAVs). Effective traffic management is a global challenge, especially in urban areas with many intersections. Much research has focused on solving this problem to increase intersection network performance. Reinforcement learning (RL) is a new approach to optimising traffic signal lights that overcomes the disadvantages of traditional methods. In this paper, we propose an integrated approach that combines the multi-agent advantage actor-critic (MA-A2C) and smart navigation (SN) to solve the congestion problem in a road network under mixed traffic conditions. The A2C algorithm combines the advantages of value-based and policy-based methods to stabilise the training by reducing the variance. It also overcomes the limitations of centralised and independent MARL. In addition, the SN technique reroutes traffic load to alternate paths to avoid congestion at intersections. To evaluate the robustness of our approach, we compare our model against independent-A2C (I-A2C) and max pressure (MP). These results show that our proposed approach performs more efficiently than others regarding average waiting time, speed and queue length. In addition, the simulation results also suggest that the model is effective as the CAV penetration rate is greater than 20%

Experiment and FEM Modelling of Bond Behaviors between Pre-stressing Strands and Ultra–High–Performance Concrete

The objective of this paper is to investigate the bond properties of prestressing strands embedded in Ultra–High–Performance Concrete (UHPC).The UHPC was made in laboratory using local materials in Vietnam.Its mixture contains: silica aggregates, portland cement PC40, fly ash, silica fume, polycarboxylate superplasticizer and the micro steel fibers.The experimental process is realized on a pull-out test. The volume fraction of micro steel fibers in UHPC was 2%. The prestressing strand with diameters of 15.2mm was considered. The interface shear strength between strand and UHPC is identified based on the results of force and displacement obtained during the pull-out test. The Cohesive Zone Model (CZM) is implemented in finite element model to study this interface behavior. This model described by a piecewise linear elastic law. The CZM’s parameters are identified based on experimental results of pull-out test.The numerical studies are used the CZM in ANSYS software. Two numerical tests are realized and compared with experimental results: pull-out test and other test to verify the deflection of I girder due to prestressing force

Experiment and FEM Modelling of Bond Behaviors between Pre-stressing Strands and Ultra–High–Performance Concrete

The objective of this paper is to investigate the bond properties of prestressing strands embedded in Ultra–High–Performance Concrete (UHPC).The UHPC was made in laboratory using local materials in Vietnam.Its mixture contains: silica aggregates, portland cement PC40, fly ash, silica fume, polycarboxylate superplasticizer and the micro steel fibers.The experimental process is realized on a pull-out test. The volume fraction of micro steel fibers in UHPC was 2%. The prestressing strand with diameters of 15.2mm was considered. The interface shear strength between strand and UHPC is identified based on the results of force and displacement obtained during the pull-out test. The Cohesive Zone Model (CZM) is implemented in finite element model to study this interface behavior. This model described by a piecewise linear elastic law. The CZM’s parameters are identified based on experimental results of pull-out test.The numerical studies are used the CZM in ANSYS software. Two numerical tests are realized and compared with experimental results: pull-out test and other test to verify the deflection of I girder due to prestressing force

Novel Human Parechovirus, Sri Lanka

Of 362 fecal samples collected from children with acute gastroenteritis in Sri Lanka during 2005–2006, 30 (8.3%) were positive for human parechovirus (HPeV) by reverse transcription–PCR. A novel HPeV, designated as HPeV10, was identified in 2 samples by sequence analysis of the viral protein 1 gene of the detected HPeVs

Extraction of anthocyanins from Butterfly pea (Clitoria ternatea L. Flowers) in Southern Vietnam: Response surface modeling for optimization of the operation conditions

In this paper, the Response Surface Methodology (RSM), in conjunction with Central Composite Design (CCD), was used to optimize the extraction of anthocyanins from Butterfly pea (Clitoria ternatea L.Flowers) cultivated in Southern Vietnam. The effect of extraction temperatures of solvent ethanol (50-70 °C), duration of extraction (40-50 min) and solid-liquid ratios (20:1-30:1) was measured as independent variables on the total extraction anthocyanins in the response function. The highest anthocyanin content of 132.756 mg/L of butterfly pea anthocyanin was collected at the solid liquid ratio of 23:1, extraction time of 46 min, and temperature 60.6°C. Butterfly pea anthocyanins yield detailed significant correlation with high F values, low P values (<0.0001), and desirable determination coefficient (R2 = 0.9994)

Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology.

BACKGROUND: Ventilator-associated respiratory infection (VARI) is a significant problem in resource-restricted intensive care units (ICUs), but differences in casemix and etiology means VARI in resource-restricted ICUs may be different from that found in resource-rich units. Data from these settings are vital to plan preventative interventions and assess their cost-effectiveness, but few are available. METHODS: We conducted a prospective observational study in four Vietnamese ICUs to assess the incidence and impact of VARI. Patients ≥ 16 years old and expected to be mechanically ventilated > 48 h were enrolled in the study and followed daily for 28 days following ICU admission. RESULTS: Four hundred fifty eligible patients were enrolled over 24 months, and after exclusions, 374 patients' data were analyzed. A total of 92/374 cases of VARI (21.7/1000 ventilator days) were diagnosed; 37 (9.9%) of these met ventilator-associated pneumonia (VAP) criteria (8.7/1000 ventilator days). Patients with any VARI, VAP, or VARI without VAP experienced increased hospital and ICU stay, ICU cost, and antibiotic use (p < 0.01 for all). This was also true for all VARI (p < 0.01 for all) with/without tetanus. There was no increased risk of in-hospital death in patients with VARI compared to those without (VAP HR 1.58, 95% CI 0.75-3.33, p = 0.23; VARI without VAP HR 0.40, 95% CI 0.14-1.17, p = 0.09). In patients with positive endotracheal aspirate cultures, most VARI was caused by Gram-negative organisms; the most frequent were Acinetobacter baumannii (32/73, 43.8%) Klebsiella pneumoniae (26/73, 35.6%), and Pseudomonas aeruginosa (24/73, 32.9%). 40/68 (58.8%) patients with positive cultures for these had carbapenem-resistant isolates. Patients with carbapenem-resistant VARI had significantly greater ICU costs than patients with carbapenem-susceptible isolates (6053 USD (IQR 3806-7824) vs 3131 USD (IQR 2108-7551), p = 0.04) and after correction for adequacy of initial antibiotics and APACHE II score, showed a trend towards increased risk of in-hospital death (HR 2.82, 95% CI 0.75-6.75, p = 0.15). CONCLUSIONS: VARI in a resource-restricted setting has limited impact on mortality, but shows significant association with increased patient costs, length of stay, and antibiotic use, particularly when caused by carbapenem-resistant bacteria. Evidence-based interventions to reduce VARI in these settings are urgently needed

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

A strategic market research for Valio LTD. : Vietnamese powdered milk market analysis

Valio Ltd, a Finnish owned dairy producer, is the market leader and guardian of Finnish healthy lifestyle. Beyond the success in European market, the company is now aiming to other destinations in Asia. Vietnam, an emerging market in Southeast Asia with large population, has a great demand for dairy products as well as other consumer goods. It is estimated to be among the 20 biggest milk importers in the world, and the amount of powdered milk imported is increasingly high. This study, commissioned by Valio Ltd, is an initial attempt to investigate the potential of Vietnamese dairy industry by undertaking a specific research on powdered milk market as well as the consumer purchasing habits and product interests, based on which the company may have proper strategies for its business expansion later on. To achieve this goal, an external analysis of the country, the powdered milk industry and consumer behaviors are entirely studied on. The market research was conducted using both qualitative and quantitative methods, based on deductive approach. With a theoretical framework provided in the literature part, secondary data was collected from academic reports, articles and other legal documents; meanwhile primary data was obtained from interviews with expert and a consumer group, a survey on consumer habits and authors’ own observations to analyze the market for the empirical section. By way of conclusion, Vietnam is a very fast developing market where the consumption of powdered milk products is emerging. Likewise, the demand for new powdered milk as well as free lactose products is also favorable these days. Although there are evitable obstacles and challenges the company should take into consideration prior to making the internationalization, this market has many advantages that may not be found in other countries. Finally, the authors positively recommend Valio to expand its product portfolio to this promising destination

Recent Research in Cell Stress and Microbial Infection

Microbial infection, including bacterial, viral, fungal, and parasitic, is a common human disease leading to various cell stresses [...